BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lindholm CR, Siegel CA. Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials? Curr Pharm Des 2019;25:64-8. [PMID: 30864506 DOI: 10.2174/1381612825666190312113935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Argollo M, Danese S. Novel Targets for Therapeutic Intervention in Inflammatory Bowel Disease: Research Drives Clinic. Curr Pharm Des 2019;25:5-6. [PMID: 31190642 DOI: 10.2174/138161282501190514105602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Xu M, Cen M, Chen X, Chen H, Liu X, Cao Q. Correlation between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease. Biomed Res Int 2019;2019:6517549. [PMID: 31950048 DOI: 10.1155/2019/6517549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Ma L, Pang X, Ji G, Ma X, Li J, Chang Y, Ma C. Application of the neutrophil to lymphocyte ratio in the diagnosis and activity determination of ulcerative colitis: A meta-analysis and systematic review. Medicine (Baltimore) 2021;100:e27551. [PMID: 34678891 DOI: 10.1097/MD.0000000000027551] [Reference Citation Analysis]
4 Zhou Z, Zhang Y, Yang X, Pan Y, Li L, Gao C, He C. Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease. Front Immunol 2022;13:865968. [DOI: 10.3389/fimmu.2022.865968] [Reference Citation Analysis]